Abbott Laboratories (ABT): Price and Financial Metrics
Abbott Laboratories (ABT)
Today's Latest Price: $106.41 USD
Updated Nov 25 7:00pm
Add ABT to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
ABT Stock Summary
- ABT has a market capitalization of $188,596,995,834 -- more than approximately 99.22% of US stocks.
- Abbott Laboratories's stock had its IPO on January 1, 1986, making it an older stock than 92.97% of US equities in our set.
- The price/operating cash flow metric for Abbott Laboratories is higher than 85.65% of stocks in our set with a positive cash flow.
- Stocks with similar financial metrics, market capitalization, and price volatility to Abbott Laboratories are TMO, CSCO, PFE, NVS, and PEP.
- ABT's SEC filings can be seen here. And to visit Abbott Laboratories's official web site, go to www.abbott.com.
ABT Stock Price Chart Interactive Chart >
ABT Price/Volume Stats
| Current price | $106.41 | 52-week high | $115.14 |
| Prev. close | $107.61 | 52-week low | $61.61 |
| Day low | $105.63 | Volume | 6,224,141 |
| Day high | $108.40 | Avg. volume | 6,940,470 |
| 50-day MA | $108.38 | Dividend yield | 1.35% |
| 200-day MA | $95.88 | Market Cap | 188.60B |
Abbott Laboratories (ABT) Company Bio
Abbott Laboratories manufactures and sells health care products worldwide. The company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company was founded in 1888 and is based in Abbott Park, Illinois.
ABT Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $106.41 | $34.43 | -69% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Abbott Laboratories. To summarize, we found that Abbott Laboratories ranked in the 22th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Abbott Laboratories ended up being:
- The company has produced more trailing twelve month cash flow than 90.62% of its sector Healthcare.
- The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 21.78% of the free cash flow producing stocks we're observing.
- ABT's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 38.27% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -70% |
| 1% | -69% |
| 2% | -69% |
| 3% | -69% |
| 4% | -68% |
| 5% | -68% |
Want more companies with a valuation profile/forecast similar to that of Abbott Laboratories? See ENDP, CPIX, DHR, EHC, and RHE.
Loading social stream, please wait...